HCG 4,100 Units/vial Injection, Anderson Compounding Pharmacy 310 Bluff City Hwy, Bristol, TN.
Published April 24, 2019 · Recall initiated: April 2, 2019
Summary
FDA records drug Class II recall D-1154-2019, published April 24, 2019 and initiated April 2, 2019. Recalling firm: Anderson Compounding Pharmacy, Inc. DBA Anderson Compounding Pharmacy; Status: Terminated; Reported quantity: 1 vial; Lot: All Lots. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of sterility assurance.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Anderson Compounding Pharmacy, Inc. DBA Anderson Compounding Pharmacy
- Distributor
- Nationwide
- Lot
- All Lots
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAHeparin 10 mL/Marcain 0.25% 20 mL/Sodium Bicarbonate 8.4%-40 mL/per 70 mL, Anderson Compounding Pharmacy 310April 24, 2019
- FDAHCG 23 Day, 2876 Units/4.6 mL Vial, Anderson Compounding Pharmacy 310 Bluff City Hwy, Bristol, TN.April 24, 2019
- FDAHeparin 10 mL/Marcaine 0.25% 20 mL/Sodium Bicarbonate 40 mL/Normal Saline 5 mL per 75 mL, 60 mL Syringe,April 24, 2019
- FDAHeparin 2 mL/Lidocaine 2%-10 mL/Sodium Bicarbonate 8.4%-5mL/ Sterile Water 10 mL, Anderson CompoundingApril 24, 2019
- FDAHCG 23 Day Injection Extra Strength, vials, Anderson Compounding Pharmacy 310 Bluff City Hwy, Bristol, TNApril 24, 2019
- FDAHeparin 20,000 U/Lidocaine 2% 10 mL/Sodium Bicarbonate 8.4% 10 mL/Sterile Water 5 mL, 27 mL Syringe, AndersonApril 24, 2019
Questions about this recall
Was HCG 4,100 Units/vial Injection, Anderson Compounding Pharmacy 310 Bluff City Hwy, Bristol, TN. recalled?
Yes. FDA published recall D-1154-2019 on April 24, 2019. Reported hazard: Lack of sterility assurance.
What should I do if I have this product?
Voluntary: Firm initiated · Letter